Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR882 Single Ascending Dose Study in Healthy Men
NCT04347005Phase 1Completed
- Sponsor
- Arthrosi Therapeutics
- Start
- Jan 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pozdeutinurad in gout and hyperuricemia (9 arms), sponsored by Arthrosi Therapeutics. Primary endpoints: Incidence of abnormal laboratory findings at 8 Days, Area under the curve for plasma AR882 at 6 Days and 5 more. Started Jan 2019; status: completed.
02
Drugs
pozdeutinurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT04347005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04347005.